



## PRESS RELEASE

21<sup>st</sup> June 2006

### QSV Biologics, Ltd., and Proteon Therapeutics, Inc., Enter into a Contract for Process Development and Manufacture of PRT-201

**QSV Biologics, Ltd** (QSV), a North American based biologics CMO located in Edmonton, Canada, and **Proteon Therapeutics, Inc.**, of Waltham, Massachusetts and Kansas City, Missouri, announced today the signing of a contract for process development and manufacturing of PRT-201, Proteon's lead drug candidate. QSV will be responsible for technology transfer, process development, scale up and pre-clinical production in their licensed cGMP manufacturing facility. PRT-201 is a novel recombinant human protein produced from yeast. In pre-clinical studies conducted thus far, PRT-201 treatment leads to permanent dilation of blood vessel segments.

Graeme Macaloney *PhD, PEng*, QSV President & CEO said: "*Proteon's first product, PRT-201 has an aggressive development track and a potentially rapid path to commercialization. Our job here at QSV is to keep process development and manufacture off the critical path and facilitate Proteon meeting its key milestones towards this objective*".

Nicholas Franano *MD*, Proteon CSO commented: "*We have been extremely impressed by the quality and responsiveness of QSV and look forward to a long and mutually beneficial relationship.*"

**Proteon Therapeutics, Inc** is a privately held biotechnology company developing novel, first-in-class pharmaceuticals to address the critical, rapidly expanding medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. For more information about Proteon, please visit: [www.proteontherapeutics.com](http://www.proteontherapeutics.com)

**QSV Biologics, Ltd.**, based in Edmonton, Canada, is an international GMP biologics contract manufacturer (CMO) providing clinical and commercial microbial fermentation, mammalian cell culture, and purification services. QSV has a Health Canada Establishment License for manufacturing clinical trial and commercial biologics and was the recipient of the Frost & Sullivan "Customer Value Enhancement Award" in 2005. QSV's market consists of global bio/pharma firms with protein therapeutics, monoclonal antibodies, vaccines & diagnostics. As a dedicated CMO with no competing products of its own, QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality & Speed build Value. For more information about QSV, please visit: [www.qsvbiologics.com](http://www.qsvbiologics.com).

For more information, please contact:

Richard Hetrick  
Director of Business Development  
QSV Biologics, Ltd.  
(780) 438 – 5722

Nicholas Franano, MD  
Chief Scientific Officer  
Proteon Therapeutics, Inc.  
(816) 531 – 0028